^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Acute Myelogenous Leukemia
    Drug:cytarabine (DNA synthesis inhibitor, DNA-directed DNAP inhibitor) +
    idarubicin hydrochloride (Topoisomerase II inhibitor, DNA cross linking agent)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    AML:…after standard-dose cytarabine induction...standard-dose cytarabine with idarubicin or daunorubicin